Medpace Holdings, Inc. Common Stock (MEDP) — 分析摘要
Medpace Holdings, Inc. Common Stock(MEDP)的市值为15.14十亿美元,最近一年的营收同比增长了+20.0%。净利润率为17.8%。当前市盈率为32.9倍。
核心要点
- 营收同比变化+20.0%
- 净利润率17.8%
- 市盈率32.9倍
与SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH板块的其他公司相比,MEDP的营收增长为+20.0%,市盈率为32.9倍。
Medpace Holdings, Inc. Common Stock (MEDP)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号,应与估值结果一并解读。
流动比率为 0.85x — 流动负债超过流动资产
营业利润率 (21.0%) 超过毛利率 (0.0%) — 请检查其他营业收入或数据分类问题
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
行业
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
员工人数
6,300
总部
CINCINNATI, OH
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。